Table 2.
Risk of Malignancy (ROM) per each category of the Bethesda system compared with other series.
| TBSRTC category on FNA | ROM in our study (N = 188) | Limlunjakorn et al. (2017)1 (N = 457) | Cibas et al. (2009)2 (Estimated) | Bongiovanni et al. (2012)3 (N = 6362) | Sheffield et al. 20144 (N = 8044) | Krauss et al. 20165 (N = 8214) |
|---|---|---|---|---|---|---|
| Non-diagnostic | 20% | 19% | 1–4% | 16.8% | 18.7% | 12% |
| Benign | 4% | 14% | 0–3% | 3.7% | 6.5% | 5% |
| Atypical of undetermined significance | 9% | 38% | 5–15% | 15.9% | 28.3% | 17% |
| Follicular Neoplasm | 24% | 21% | 15–30% | 26.1% | 33.1% | 25% |
| Suspicious for malignancy | 57% | 82% | 60–75% | 75.2% | 65% | 72% |
| Malignant | 90% | 94% | 97–99% | 98.6% | 98.6% | 98% |
1
Limlunjakorn P, et al. J Med Assoc Thai 2017;100:783–92.
2
Cibas ES, et al. Am J Clin Pathol 2009;132:658–65.
3
Bongiovanni M, et al. Acta Cytol 2012;56:333–9.
4
Sheffield BS, et al. Expert Rev Endocrinol Metab 2014;9:97–110.
5
Krauss EA, et al. Arch Pathol Lab Med 2016;140:1121–31.